## **Core Concept**
The patient's complaint of shortness of breath after taking aspirin suggests an adverse reaction to the medication, potentially related to its mechanism of action on prostaglandins and leukotrienes. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes. This inhibition affects the synthesis of prostaglandins and thromboxanes from arachidonic acid.

## **Why the Correct Answer is Right**
The correct answer, **C. Cysteinyl leukotriene receptor antagonist**, relates to the mechanism by which aspirin can induce bronchospasm and shortness of breath in sensitive individuals, particularly those with asthma. Aspirin inhibits the COX pathway, diverting arachidonic acid metabolism towards the lipoxygenase pathway, which results in increased production of leukotrienes. Leukotrienes are potent bronchoconstrictors. In aspirin-exacerbated respiratory disease (AERD), the increased leukotriene production leads to severe bronchospasm and shortness of breath. A cysteinyl leukotriene receptor antagonist would mitigate this effect by blocking the action of leukotrienes on their receptors, thereby reducing bronchoconstriction.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because it does not directly relate to the mechanism by which aspirin causes shortness of breath. While histamine is involved in allergic reactions and can cause bronchoconstriction, the specific pathway involved in aspirin's effect is related to leukotrienes.
- **Option B:** This option is incorrect as it suggests a preventive measure (a beta-agonist) rather than an explanation for the mechanism or a related therapeutic approach to mitigate the effect.
- **Option D:** This option is incorrect because, while an antihistamine might help with allergic symptoms, it does not address the specific mechanism of aspirin-induced bronchospasm, which is primarily mediated by leukotrienes.

## **Clinical Pearl / High-Yield Fact**
Aspirin-exacerbated respiratory disease (AERD) is a condition where patients have chronic rhinosinusitis with nasal polyps, asthma, and sensitivity to aspirin and other NSAIDs, leading to severe respiratory symptoms. A key clinical pearl is that patients with AERD can often be managed with leukotriene modifiers, which help control symptoms by blocking the effects of leukotrienes.

## **Correct Answer:** C. Cysteinyl leukotriene receptor antagonist.